Gain -Model See-Tx -Site-Directed Enzyme Enhancement Therapy (See-Tx) Platform
Gain is utilizing its Site-Directed Enzyme Enhancement Therapy (See-Tx™) platform to guide misfolded enzymes back into their proper shape in order to treat a range of diseases.
See-Tx™ is a computational platform that uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The output from the See-Tx™ platform are newly discovered binding sites that for the first time, can be targeted for therapeutic benefit to correct enzyme misfolding, thus restoring function and eliminating the subsequent toxic substrate buildup that causes disease.
DIFFERENTIATED and PATENTED Highly-specific, efficient and cost-effective drug discovery approach.
- Identify
Using the 3D structure of proteins and supercomputing technology, SEE-TxTM identifies novel druggable binding hotspots
- Screen & Select
Utilizing proprietary screening methodology, SEE-TxTM filters up to 10 million compounds to select a pool of candidates that may bind to the novel druggable hotspots
- Optimize
Gain optimizes this pool of small molecules to identify and develop proprietary STARs that stabilize misfolded proteins and to restore their biological activity